Diagnostics
C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located.
Depression is the first indication, but other neurological conditions are being planned.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.
Eriksson said that HMNC Brain Health is a pioneer in developing precision medicine for the psychiatric space.
Several life sciences companies were sprinkled throughout this year’s list. Here’s a look at a few of the honorees.
The duo’s mission is to identify more patients who could benefit from precision medicines by deploying more CDx tests to healthcare providers.
This is an effort to eliminate severe adverse reactions by matching the birth control to the genetics and hormones of the individual.
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.
PRESS RELEASES